Biotech | April 20, 2026
Loopworm’s silkworm-based ingredients found carbon negative in PwC-backed study
The study was conducted by PwC India in line with ISO 14040 and ISO 14044 protocols
The study was conducted by PwC India in line with ISO 14040 and ISO 14044 protocols
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
Subscribe To Our Newsletter & Stay Updated
